Printer Friendly

Boehringer Ingelheim extends collaboration with University of Dundee.

M2 PHARMA-June 13, 2019-Boehringer Ingelheim extends collaboration with University of Dundee

(C)2019 M2 COMMUNICATIONS

It was reported yesterday that Germany-based Boehringer Ingelheim has extended its collaboration with the University of Dundee to develop new medicines that target and destroy cancer causing proteins.

The agreement partners Professor Alessio Ciulli, one of the pioneers in the field of Proteolysis targeting chimeras, based in the School of Life Sciences at Dundee, with Boehringer Ingelheim's pharmaceutical expertise.

Darryl B. McConnell, PhD, Senior Vice President and Research Site Head, Boehringer Ingelheim, Vienna, Austria, said, 'PROTACs are a disruptive therapeutic modality which are bringing previously deemed undruggable targets within reach. Our collaboration will continue to work to bring this new class of medicines to patients. The joint team is making rapid progress and have successfully reached the first collaboration milestone setting a solid basis for achieving our goals.'

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jun 13, 2019
Words:154
Previous Article:USFDA approves Merck's anti-PD-1 therapy Keytruda.
Next Article:Novartis' Cosentyx achieves endpoints in psoriatic arthritis study.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters